Healthcare dealmakers gathering in San Francisco for the industry's premier annual conference this week say they expect a ...

Industry leaders from more than 500 companies scheduled to give investor presentations will see heightened security ...

Even if you enjoy average annual returns of just 8%, that can make you a lot richer over long periods. And you can certainly ...

A non-opioid painkiller from Vertex Pharmaceuticals could become a blockbuster, but questions remain on whether it will prove ...

Andy Extance charts how research into revolutionary targeted protein degradation therapies is moving from serendipity to ...

Five years after the COVID-19 pandemic hit South Carolina and the U.S., it is still changing health care, from wastewater ...

Pfizer is expected to rebound in 2025 with growth stabilized and dividend growth to continue. Learn why PFE stock is a Buy.

EY—the professional services firm originally known as Ernst & Young—reports the dollar value of biopharma M&A deals nosedived ...

Korean drugmakers hold over 50% market share in the 6 best-selling biosimilar markets, 2 companies sign exclusive licensing ...

Charleston, W.Va. (WTAP) - West Virginia Attorney General Patrick Morrisey has sent letters to all of the state’s counties ...

Though Pfizer Inc.’s work on a PD-1-targeting antibody has trailed far behind that of its fellow big pharmas, the company could be the first to market in treatment-naïve, high-risk non-muscle invasive ...

A federal appeals court revived a lawsuit on Friday challenging Pfizer Inc.‘s fellowship program aimed at building a diverse ...